63: GLP-1s in Practice: Your Top Questions Answered

When we hosted The GLP-1 Journey: Supporting Clients Before, During, and After GLP-1s on June 11, 2026, with Dr. Holly Lucille, ND, RN, Senior Medical Advisor at Fullscript, we knew the topic would resonate. Hundreds of questions and comments came from practitioners across every corner of nutrition and healthcare.

We covered as much ground as we could live. But so many of those questions deserved a real, thorough answer. This post and the companion podcast episode are our response to that.

NOTE: The content here was curated with support from the Fullscript medical advisory team. It is educational in nature and is not medical advice. For individual patient decisions around dosing, titration, and medication management, those conversations belong between your patient and their prescribing physician. Our goal is to give you a stronger clinical foundation so you can be a better partner in that process.

We pulled the five themes that came up repeatedly: protein and muscle preservation, GI management, long-term questions about plateaus and de-escalation, safety concerns that deserve a straight answer, and natural GLP-1 support and supplements.

Protein and Muscle Preservation on GLP-1s

How Much Protein Does Your Patient Actually Need?

This was the number-one question across all categories, and the confusion is understandable. General population recommendations sit around 0.8 grams per kilogram of body weight. Updated guidelines pushed that to 1.2 to 1.6. And then you have GLP-1 patients, in a significant caloric deficit, potentially losing weight rapidly, and at real risk for muscle loss. Which number applies?

For patients on GLP-1s, 1.2 to 1.6 grams per kilogram is your floor, not your target. The evidence supports targeting 1.2 to 2.0 grams per kilogram of body weight per day for this population, with higher targets warranted for older adults, those losing weight rapidly, or patients at elevated risk of sarcopenia.

IBW vs. AdjBW: Which Body Weight Do You Use?

Actual body weight tends to overestimate protein needs in patients with significant obesity. Ideal body weight alone may underestimate them. The most clinically appropriate reference point may be adjusted body weight, which accounts for the metabolically active lean tissue present in excess weight. Ultimately, this is a clinical decision that takes into account the individual patient journey.

The formula: AdjBW = IBW + 0.25 × (ABW − IBW)

Many GLP-1 clinicians use IBW or adjusted body weight at 1.2 to 1.6 grams per kilogram as a pragmatic starting point, with room to go higher when muscle preservation is the priority.

The Practical Challenge

Appetite suppression on GLP-1s makes hitting even the lower end of the protein range genuinely difficult for many patients. They are simply not hungry. This is why protein-first meal structure is non-negotiable in this population. Every eating occasion starts with protein. Supplementation – protein powder, Greek yogurt, cottage cheese, eggs, fish – becomes a bridge to meeting targets on days when appetite is low.

Why Lean Mass Loss Is the Real Risk

Scale weight alone will never tell you what you need to know about a GLP-1 patient. When lean mass makes up more than 30 to 35 percent of total weight lost, that is a clinical flag. Above 40 percent, you are looking at sarcopenic obesity risk and potential malnutrition. Body composition monitoring needs to be standard of care for these patients, not an optional add-on.

In an outpatient setting, InBody or equivalent medical-grade bioelectrical impedance analysis is the recommended tool. It is fast, non-invasive, and provides segmental lean mass, body fat percentage, visceral fat, and total body water, all clinically relevant for GLP-1 monitoring. For practices considering adding this capability, the business case is real: it differentiates your clinical offering, supports higher-level decision-making, and directly demonstrates the value of nutritional intervention in a way a scale never will.

Creatine as a Practitioner-Recommended Add-On

Creatine monohydrate is one of the most evidence-supported supplements for lean mass preservation and belongs in your GLP-1 toolkit. The mechanism is straightforward: creatine increases phosphocreatine stores in muscle, supporting performance during resistance training and muscle protein synthesis over time.

For this population, skip the loading phase and go straight to a maintenance dose of 3 to 5 grams per day. One important caveat: creatine draws water into muscle cells, which can theoretically contribute to constipation in patients who are already under-hydrated. Confirm hydration targets are solid before adding them.

The protective triad for this population is adequate protein, resistance training two to three times per week, and consistent meal timing. Those three work together. None of them works as well without the others.

2. Managing GI Side Effects

Why GI Symptoms Happen Even at Low Doses

GI symptoms are the number one reason patients struggle to stay on GLP-1 medications. And one of the most common misconceptions is that a low starting dose means a low GI burden. That is not how it works. GLP-1 receptors in the GI tract respond immediately to even small drug concentrations. There is no true sub-therapeutic dose from a GI standpoint.

Patients who begin the medication without having built a dietary foundation first – protein-first eating, smaller meal sizes, optimized hydration – experience more pronounced symptoms. If you have any touchpoints with a patient before they start a GLP-1, use it to build that foundation. It makes a measurable difference.

The Low and Slow Framework

Once symptoms are present, the approach is low-and-slow.

For protein: start modestly above baseline and titrate up weekly. Prioritize easily digestible, low-residue sources – eggs, Greek yogurt, cottage cheese, fish, hydrolyzed protein powders. Avoid high-fat protein sources like red meat and anything fried, which further slow gastric emptying.

For fiber: temporarily reduce to 10-15 grams per day during active symptom phases, then rebuild slowly by adding 2-3 grams per week. Soluble fiber is better tolerated than insoluble fiber during symptomatic periods. Oats, psyllium, and well-cooked vegetables. The raw vegetables, cruciferous vegetables, and legumes that are normally excellent choices become common culprits when gastric emptying is significantly delayed.

For meal structure: smaller, more frequent meals reduce gastric pressure, but avoid going beyond three to four eating occasions per day. More frequent eating means the stomach is rarely empty, creating fermentation, gas, and distension. Allow four to five hours between meals for adequate gastric clearance.

Cooked vs. Raw Vegetables: The Rationale

The recommendation to favor cooked vegetables on GLP-1s is not arbitrary. Raw vegetables contain higher levels of insoluble fiber and intact cell walls, which require significant digestive effort. On a GI tract where emptying is already delayed, adding a large raw vegetable load compounds bloating and gas. Cooking also breaks down fermentable carbohydrates in cruciferous vegetables and alliums, reducing the FODMAP burden.

Practical guidance: steam, roast, or sauté vegetables until soft. Peel where possible to further reduce insoluble fiber load. Introduce raw vegetables gradually as GI symptoms stabilize. Low-FODMAP cooked vegetables to start include zucchini, carrots, green beans, spinach, and sweet potato.

SIBO: The Risk Most Practitioners Are Not Watching For

This came up strongly in the Q&A and warrants direct attention. The mechanistic case for elevated SIBO risk on GLP-1s is real. These medications slow gastric emptying and reduce GI motility, which can impair the migrating motor complex that normally keeps bacterial populations in check in the small intestine.

If you have a patient with persistent bloating, gas, alternating diarrhea and constipation, or malabsorption that is not resolving with standard GI management strategies, SIBO needs to be on your radar. Hydrogen and methane breath testing is the standard diagnostic tool. This is a conversation to facilitate with their physician.

Supplement Support for GI Symptoms

SunFiber (partially hydrolyzed guar gum) is one of the best-tolerated supplemental fiber options for this population. Low-FODMAP certified, dissolves completely, and improves stool consistency without worsening bloating. Start at 5 grams per day and titrate up.

Digestive enzymes are reasonable to trial, particularly broad-spectrum formulations with lipase, protease, and amylase. Delayed gastric emptying may reduce the efficiency of endogenous enzyme mixing.

TUDCA (tauroursodeoxycholic acid) is worth knowing about, especially for patients who have had their gallbladder removed or have biliary symptoms, given that GLP-1s alter bile acid metabolism and increase the risk of gallstones. Typical dose: 250 to 500 milligrams with meals.

A clear scope note: if a patient is having bowel movements as infrequently as once a month, that is not a nutrition adjustment situation. Persistent severe abdominal pain, signs of obstruction, and symptoms that go beyond the expected GI side effect profile are medical referrals, not dietary modifications.

3. The Long-Term Question: Plateaus, Switching, and De-escalation

Why Plateaus Happen — and Why They Are Not Failure

Weight loss plateaus on semaglutide are well documented and typically occur around the 60- to 68-week mark. This is not a sign that the medication stopped working or that the patient did something wrong. It reflects normal metabolic adaptation: resting metabolic rate decreases as weight is lost, hunger hormones partially compensate over time, and the body reaches a new homeostatic set point at a given dose. This is physiology, not failure, and that reframe matters enormously for patient retention and motivation.

Semaglutide to Tirzepatide: What the Data Shows

When a patient has plateaued on semaglutide, switching to tirzepatide is a conversation worth having with their prescriber. Tirzepatide targets both GLP-1 and GIP receptors, and real-world data and case series show that switching can produce an additional 5 to 15 percent weight loss in patients who have plateaued. The SURMOUNT-5 trial provided further evidence of tirzepatide’s greater weight-loss outcomes compared with semaglutide in a head-to-head comparison.

From a nutrition standpoint, treat a medication switch like a new initiation. GI side effects can re-emerge. Restart all dietary strategies for nausea and GI management. Use the transition as an opportunity to reassess body composition and nutritional status before the new medication takes full effect.

Reframing GLP-1 as Chronic Disease Management

The most important framing shift for long-term GLP-1 conversations is this: obesity is a chronic, relapsing disease. It is comparable to hypertension or hyperlipidemia in that it often requires long-term management, sustained lifestyle intervention, and, in many cases, ongoing pharmacotherapy. When practitioners frame GLP-1 therapy through that lens, long-term use stops being a failure. It is appropriate disease management. Patients need to hear this from you.

The De-escalation Framework

For patients who want to work toward coming off the medication, a structured three-phase approach provides a realistic and evidence-informed pathway.

Phase 1 — Foundation Building: This happens during active treatment and is the most important phase. Patients who build strong nutritional habits, consistently hit protein targets, establish a resistance-training routine, and develop structured meal timing during treatment are in the best possible position for a successful transition off treatment.

Phase 2 — Gradual Dose Reduction: Reduce the dose every 4 to 6 weeks with close monitoring. This is managed entirely by the prescribing physician; our role is to support the nutritional foundation throughout.

Phase 3 — Medication-Free Maintenance: Supported by the behavioral and nutritional habits built in phases one and two.

The honest answer to the question patients are really asking – will I regain the weight? Is significant weight regain common after discontinuation without a strong behavioral foundation? That is also the strongest argument for prioritizing habit-building throughout the entire treatment period, not just at the end. The medication creates a window. What the patient builds during that window determines what comes after.

4. Safety Concerns, Answered Directly

Pancreatitis: What Is Real

GLP-1 receptor agonists carry an FDA label warning for pancreatitis. Clinical trial data show a small but real increase in the risk of acute pancreatitis, generally reported in the literature as roughly 0.1 to 0.3 percent, modestly above the background rate. Certain patient histories elevate that risk: personal or family history of pancreatitis, hypertriglyceridemia, and heavy alcohol use. Physicians evaluate these factors carefully before and during treatment.

As non-prescribing practitioners, our role is not to assess or diagnose. We can and should encourage patients to report any persistent severe abdominal pain, particularly if it radiates to the back or is associated with vomiting, to their care team without delay. That is good clinical communication, not an alarm.

Pancreatic Cancer: What the Evidence Actually Shows

The association between GLP-1 use and pancreatic cancer is not established in human clinical data. Early rodent studies raised concerns, but large-scale human pharmacovigilance studies, including a joint FDA and EMA review, did not find a significant signal. Major trials covering hundreds of thousands of patient years did not show an increased incidence. The current consensus is that this risk is not considered clinically meaningful based on available evidence. It is an evolving area, and patients should always discuss it with their physician, but it is not a reason to avoid these medications.

Why Advertising Does Not Tell the Whole Story, and Why That Is Not the Same as Hidden Risk

Pharmaceutical advertising is governed by FDA regulations requiring a fair balance between risks and benefits. The cardiovascular, metabolic, and weight-related benefits in the indicated population are substantial, while the absolute risk increase for pancreatitis is small. That shapes how advertising is weighted. The fact that advertising does not emphasize a risk is not the same as that risk being hidden. The information is in the prescribing label and in the literature. Helping patients understand that distinction is genuinely useful.

The Blood Pressure Paradox

Some patients experience increased blood pressure on GLP-1s, which feels counterintuitive given that these medications generally trend toward modest blood pressure reduction in clinical trials. Several mechanisms explain it in individual patients: transient sympathetic nervous system activation, sodium retention during rapid weight loss phases due to hormonal shifts, and, most commonly, dehydration. Thirst suppression often accompanies appetite suppression, and inadequate fluid intake causes compensatory vasoconstriction.

The clinical approach: monitor blood pressure trends over multiple readings, optimize hydration, review the full supplement and medication list, and refer back to the prescribing physician if elevation is persistent and unexplained.

Sour Food Cravings and Zinc

If a patient tells you their taste has changed or they are suddenly drawn to sour or acidic foods, think zinc before you think anything else. GLP-1 agonism can alter taste perception, but zinc deficiency, a priority micronutrient at risk in this population, is a well-established cause of taste disturbances and can manifest as cravings for sharp, acidic flavors. Check zinc status and confirm it is included in the patient’s multivitamin protocol. Fermented foods like yogurt and kefir, which often satisfy these cravings, are an excellent choice in this population anyway.

5. Natural GLP-1 Support and Supplements

The Honest Answer About Natural Alternatives

Natural GLP-1 secretagogues exist, and some of them have solid evidence. But the direct answer to patients asking whether they can replace their medication with a supplement is: no. Natural GLP-1 stimulants do not produce a comparable magnitude of effect to pharmaceutical GLP-1 receptor agonists. They are best positioned as adjuncts, supporting natural GLP-1 activity in patients who are not on medication, or as complementary support alongside it.

The Single Most Potent Natural GLP-1 Stimulus

Dietary protein. Particularly whey protein, but high-quality protein sources across the board – eggs, fish, Greek yogurt, legumes – directly stimulate L-cell GLP-1 secretion. This is another reason the protein-first meal framework is so foundational. It is not just about muscle preservation. It is metabolically active in its own right.

Foods and Compounds That Support Endogenous GLP-1 Secretion

Fermentable fiber and prebiotics: Oats, legumes, garlic, onions, leeks, green bananas, and Jerusalem artichokes feed gut bacteria that produce short-chain fatty acids, particularly butyrate and propionate, which directly stimulate GLP-1 secretion. This is the mechanistic reason the Mediterranean dietary pattern functions as a GLP-1-optimizing eating pattern by design.

Berberine: Activates AMPK and has a modest GLP-1 secretagogue effect with multiple randomized controlled trials behind it in type 2 diabetes populations. A legitimate adjunct with real evidence. Not a pharmaceutical equivalent.

Extra-virgin olive oil: Monounsaturated fats stimulate GLP-1 secretion, consistent with the Mediterranean dietary pattern.

Bitter foods: Cruciferous vegetables, dark leafy greens, and coffee activate bitter taste receptors in the gut that stimulate GLP-1 release.

Vinegar and fermented foods: Acetic acid modestly stimulates GLP-1 secretion and improves postprandial glucose response.

Resistant starch and inulin/FOS: Work through the same SCFA-mediated pathway as fermentable fiber, with reasonable supporting evidence.

On berberine specifically, patients often refer to it as “natural Ozempic.” The mechanisms overlap in some ways, but the effect size does not. Berberine has legitimate evidence for modest improvements in blood glucose and insulin sensitivity. Patients who need medication should not delay it in favor of berberine.

Ozempic Face and Collagen: What to Actually Recommend

Ozempic face, the facial volume loss and skin laxity associated with rapid weight loss on GLP-1s, is real and patients are going to ask you about it. It results from loss of subcutaneous facial fat and, in some cases, concurrent lean tissue loss.

Hydrolyzed collagen peptides (types I and III) have emerging evidence for improving skin elasticity, hydration, and density with consistent use. A typical evidence-supported dose is 10 to 15 grams per day. The critical caveat to communicate clearly to every patient: collagen is not a complete protein. It lacks tryptophan and is low in several essential amino acids. It cannot serve as a primary protein source. Patients who try to meet protein targets with collagen shakes will fall short in ways that matter clinically. Collagen is a skin-targeted supplement that sits alongside adequate protein intake, not instead of it.

The most impactful interventions for Ozempic face are adequate total protein intake, vitamin C at 500 to 1,000 milligrams per day as an essential cofactor for collagen synthesis, consistent hydration, and resistance training to preserve lean tissue. Slowing the rate of weight loss, where clinically appropriate, also gives skin more time to adapt.

A Note on Pendulum’s GLP-1 Probiotic Pro

Several practitioners asked about this product. The mechanistic rationale is scientifically plausible; it is formulated with strains including Akkermansia muciniphila and butyrate-producing bacteria to support endogenous GLP-1 secretion through gut microbiome modulation. Akkermansia has demonstrated metabolic benefits in human trials, and butyrate is a known GLP-1 secretagogue. The limitation is that most supporting data comes at the individual strain level rather than the proprietary blend level. It is a reasonable adjunct to consider for patients focused on gut health alongside GLP-1 therapy. Position it honestly: promising mechanistic rationale, limited product-specific clinical evidence, not a pharmaceutical equivalent.

Content Cure: Access the Event Recording, Full Q&A PLUS Resources

To access the complete 52-question Q&A document, the full webinar replay, and the GLP-1 Toolkit, register >>HERE<<

This content was developed in collaboration with the Fullscript medical advisory team for educational purposes. It is not intended as medical advice. Individual patient decisions should always involve the patient’s prescribing physician. For the full reference list, see the Q&A document in Content Cure above.